BARDA Announces the 74th Food and Drug Administration Approval/Licensure/Clearance for Medical Countermeasures Supported by BARDA Under Novel-public Private Partnerships

Excerpt:  “At Biomedical Advanced Research and Development Authority (BARDA), we are excited about the news of the recent U.S. Food and Drug Administration (FDA) 510(k) clearance of the automated merged B-lines imaging feature on Lumify point‐of‐care handheld diagnostic ultrasound system (available on all three Lumify transducers) from our partner, Philips North America. This decision marks the 74th FDA approval/licensure/clearance for medical countermeasures supported by BARDA under novel public-private partnerships. This ultrasound device is handheld, improving access by enabling point of care assessment of lung injury which allows for quicker triage and clinical decision-making.”